In 2026, brain-computer interface research crossed a threshold that scientists and clinicians have been working toward for decades. What was once a laboratory curiosity - translating thought into action through a digital intermediary - has emerged as a verified medical technology with measurable outcomes, expanding clinical trial data, and a regulatory framework that is, for the first time, beginning to match the pace of the science itself.

Synchron is preparing the first pivotal clinical trial of a permanently implanted brain-computer interface in 2026, funded by a $200M Series D and aimed at the first PMA filing for an endovascular BCI.

On March 13, 2026, China’s National Medical Products Administration approved the NEO-ONE SCI, a brain-computer interface made by Neuracle Technology (博睿康), a Shanghai-based company founded in 2011 by two Tsinghua University biomedical engineering PhDs. The device reads neural signals through electrodes placed outside the dura mater without penetrating brain tissue, helping quadriplegic patients regain hand grasp function via a pneumatic glove. It is the first invasive brain-computer interface to receive regulatory clearance for commercial medical use anywhere in the world.

Scientists are also investigating neuromodulation combined with brain-computer interface (BCI) technology to maximize neuroplasticity and improve motor recovery ...

Modern approaches of signal processing for bidirectional neural interfaces. Somatosensory Feedback for Neuroprosthetics. 2021 | Book chapter. Part of DOI ...

Brain-computer interface research achieved a pivotal milestone in 2026, transitioning from experimental technology to clinically validated medical application. Multiple breakthroughs converged simultaneously, including the first rapid-calibration intracortical typing system matching able-bodied communication speeds and FDA Breakthrough Device Designations for stroke rehabilitation and treatment-resistant depression applications. Advanced artificial intelligence architectures, particularly deep learning models including transformer-based systems, now decode sparse neural signals with unprecedented accuracy, accelerating clinical deployment timelines from years to months. Expanding peer-reviewed publications established new benchmarks for motor restoration, speech neuroprosthetics, and seizure prediction. This convergence of clinical evidence, regulatory recognition, and technological maturity has captured healthcare industry attention, with hospital networks and medical investors actively exploring adoption pathways, positioning 2026 as a transformational year marking BCI's transition to mainstream clinical practice.

The IpsiHand BCI for stroke rehabilitation is a perfect example: FDA-cleared in 2021, it only got its first Medicare billing code in 2024, and major private ...

The Stentrode is an endovascular electrode array — a stent-like mesh threaded through a blood vessel on a catheter and lodged in a vein next to the motor cortex ...

Implantable brain–computer interfaces (iBCIs) decode neural signals to generate command signals for effector devices to restore lost functions, such as movement or speech. However, maintaining device performance over time requires recalibration of decoding algorithms due to inherent instability in neural signals. Objective. To systematically review recalibration procedures in iBCIs for patients with motor impairments, focusing on the clinical implications of recalibration requirements and strategies which can enable long-term, independent use. Approach. A systematic search was conducted across EMBASE, MEDLINE, and CINAHL databases to identify studies involving recalibration of iBCIs. Data on recalibration frequency, duration, staff requirements, and location were extracted and analyzed.

Biodegradable bioelectronic systems require materials that can mechanically integrate with soft tissues while minimizing long-term invasiveness. Conventional electronic materials, owing to their high stiffness, often cause mechanical mismatch with biological tissues, leading to chronic inflammation and tissue damage. To address these challenges, biodegradable conductive materials based on organic and polymeric systems have emerged as promising candidates for transient, biofriendly electronics. This review provides a comprehensive overview of recent advances in biodegradable conductive systems, including conductive polymers, conductive composite pastes, and organic mixed ionic–electronic conductors (OMIECs). The discussion covers material design strategies that simultaneously address electrical performance, mechanical compliance, and degradability in both partially and fully degradable systems. Particular attention is given to the relationships among degradation behavior, microstructure, and device stability, which play critical roles in determining functional lifetime. The scope further extends to key bioelectronic applications, including bioelectrical stimulation, drug delivery, sensing, and neuromorphic systems, demonstrating the versatility of these materials across diverse platforms. Emphasis is placed on providing an integrated perspective for the design of next-generation transient bioelectronic systems based on biodegradable organic conductors.

Synchron has officially launched the Stentrode Home Edition, marking a significant milestone for the brain-computer interface industry as the company transitions its endovascular BCI platform from clinical trial environments into supervised home-based use. The announcement, made at a neurotechnology summit in San Francisco this week, represents the first commercially authorized BCI system designed for daily independent use by patients with severe motor impairments, including those living with ALS and spinal cord injuries.

Most brain implants work brilliantly on day one. By year two, many are going quiet. The culprit isn’t bad engineering — it’s biology fighting back against foreign hardware. A team from Tsinghua University, the Chinese Academy of Sciences, and the University of Tokyo may have cracked this problem with an all-organic, hair-thin electrode array that reportedly kept firing clearly for over 18 months in animal tests. The findings, published in PNAS, suggest a fundamentally different approach to building brain-computer interfaces that last. Research into frozen brain tissue preservation represents another frontier in the broader effort to understand and protect neural function.

The most critical part is the classification rationale–Invasive/implantable BCI devices are Class III. For non‑invasive: those used for treatment, functional compensation, or other rehabilitation are Class III; only those for stroke limb rehabilitation without AI are Class II (due to mature protocols, no implant trauma, and no AI uncertainty, with controllable risks). If AI is used, because it may misinterpret intent and cause motor injury, it is still managed as Class III.

Imagine slipping into a lightweight, form-fitting garment that can silently eavesdrop on the intricate electrical dialogue between your brain and every twitching muscle fiber, all without a single drop of conductive gel or a tangle of wires snaking across your skin. That vision has just leaped from  science fiction to laboratory reality. In a study published in Nature Communications, a team of engineers and neuroscientists has unveiled a novel smart  textile  electrode array capable of mapping the full cortico-muscular axis from the body’s surface with unprecedented resolution. This is not merely an incremental upgrade to existing electrode technology; it’s a fundamental reimagining of how we capture the human body’s electrophysiological symphony, weaving sensing capability directly into the fabric of our clothes.

Brain-computer interfaces represent a transformative medical technology, yet surgical implantation presents significant limitations for global health deployment. While landmark trials like BrainGate demonstrated remarkable clinical outcomes enabling patients with tetraplegia to control robotic devices through neural signals, the procedural burden constrains enrollment speed and research iteration. Surgical BCI trials remain expensive, geographically limited, and difficult to scale to regulatory standards necessary for widespread adoption. The field's strategic shift toward non-surgical implantable alternatives addresses these evidence velocity challenges, accelerating clinical learning cycles and expanding accessibility. This transition represents more than procedural caution; it reflects a fundamental reimagining of how neurotechnology can mature into scalable, deployable health infrastructure capable of benefiting broader populations globally.

BCI devices play an essential role in the medical field. This review briefly summarizes novel wearable EEG-based BCIs applied in the medical field and the latest progress in related technologies, emphasizing its potential to help doctors, patients, and caregivers better understand and utilize BCI devices.

Endovascular neural interfaces (ENIs) offer a minimally invasive approach for neural stimulation and recording without the need for open brain surgery. However, current generation devices have long transvascular wires from the implant site to the chest. Eliminating these wires will unlock clinical usability, including lowering infection risk from transvascular wires, reducing the risk of thrombosis from altered hemodynamics, and improving mechanical reliability. However, removing these transvascular wires would require efficient power transfer across the skull and tissue while meeting specific absorption rate (SAR) limits, which is a significant challenge in the field.

Modern neuroprostheses can now restore communication in patients who have lost the ability to speak or move. However, implanting these invasive devices comes with risks inherent to neurosurgery. Here we introduce a noninvasive method to decode the production of sentences from brain activity and demonstrate its efficacy in a cohort of 35 healthy volunteers. For this, we present Brain2Qwerty, a new deep learning architecture trained to decode sentences from either electro- or magnetoencephalography, while participants typed briefly memorized sentences on a QWERTY keyboard. With magnetoencephalography, Brain2Qwerty reaches, on average, a character error rate of 29% and substantially outperforms electroencephalography (character error rate: 65%). For the best participants, the model achieves a character error rate of 18%, and can perfectly decode a variety of sentences outside of the training set. Overall, these results narrow the gap between invasive and noninvasive methods and thus open the path for developing safe brain–computer interfaces for noncommunicating patients.

The NeuroTech Company Directory represents a comprehensive database of over 563 companies operating across diverse sectors including brain-computer interfaces, cognitive health, neuromodulation, and psychedelic therapeutics. Updated weekly by an AI research agent, the directory profiles leading innovators such as COMPASS Pathways, advancing psilocybin therapy for treatment-resistant depression; Kernel, democratizing non-invasive neuroimaging technology; MindMed, developing psychedelic-derived therapeutics for psychiatric disorders; and BrainPatch, creating AI-powered brain-computer interfaces for neurological restoration. Additional companies including HABS focus on cognitive enhancement through neural interfaces. This curated resource serves as a critical intelligence tool for tracking developments in emerging neurotech sectors and identifying key players reshaping neuroscience and mental health innovation.

This research addresses the optimization of auricular vagus nerve stimulation (aVNS) therapy through predictive cardiac cycle modeling. The study evaluates four prediction methods—last value, averaging, extrapolation, and interpolation—to forecast cardiac cycle duration following R-peak detection on electrocardiogram readings. Such predictions enable personalized, cardiac-gated closed-loop aVNS delivery synchronized with specific cardiac phases, potentially enhancing therapeutic outcomes while minimizing adverse effects. Offline analysis demonstrated that respiration-sensitive methods, particularly extrapolation and interpolation, substantially outperformed respiration-insensitive approaches during deep breathing, achieving median absolute errors below 32 milliseconds. Real-time implementation across normal and paced breathing conditions validated three leading methods, establishing feasibility for clinical application of adaptive neuromodulation therapies tailored to individual physiological states.